{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:23:07Z","timestamp":1793863387232,"version":"4.6.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006988","name":"John S. Dunn Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006988","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001023","name":"Amon G. Carter Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001023","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here, we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. The fluorescence-based neutralization assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with patient specimens with other viral, bacterial, or parasitic infections. Collectively, our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.<\/jats:p>","DOI":"10.1038\/s41467-020-17892-0","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T06:05:13Z","timestamp":1597298713000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":303,"title":["A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation"],"prefix":"10.1038","volume":"11","author":[{"given":"Antonio E.","family":"Muruato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila R.","family":"Fontes-Garfias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8538-1997","authenticated-orcid":false,"given":"Mariano A.","family":"Garcia-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet D.","family":"Menachery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0918-016X","authenticated-orcid":false,"given":"Xuping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5553-1616","authenticated-orcid":false,"given":"Pei-Yong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"key":"17892_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"17892_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"17892_CR3","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.14.20065771","author":"AT Huang","year":"2020","unstructured":"Huang, A. T. et al. A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. medRxiv https:\/\/doi.org\/10.1101\/2020.04.14.20065771 (2020).","journal-title":"medRxiv"},{"key":"17892_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2196-x","author":"R Wolfel","year":"2020","unstructured":"Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature https:\/\/doi.org\/10.1038\/s41586-020-2196-x (2020).","journal-title":"Nature"},{"key":"17892_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0913-5","author":"F Amanat","year":"2020","unstructured":"Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-020-0913-5 (2020).","journal-title":"Nat. Med."},{"key":"17892_CR6","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.23.20077156","author":"CH GeurtsvanKessel","year":"2020","unstructured":"GeurtsvanKessel, C. H. et al. Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment. medRxiv https:\/\/doi.org\/10.1101\/2020.04.23.20077156 (2020).","journal-title":"medRxiv"},{"key":"17892_CR7","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.20.20091694","author":"H Harvala","year":"2020","unstructured":"Harvala, H. et al. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. medRxiv https:\/\/doi.org\/10.1101\/2020.05.20.20091694 (2020).","journal-title":"medRxiv"},{"key":"17892_CR8","doi-asserted-by":"publisher","unstructured":"Perera, R. A. et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill. 25, https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.16.2000421 (2020).","DOI":"10.2807\/1560-7917.ES.2020.25.16.2000421"},{"key":"17892_CR9","doi-asserted-by":"publisher","unstructured":"Okba, N. M. A. et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients. Emerg. Infect. Dis. 26, https:\/\/doi.org\/10.3201\/eid2607.200841 (2020).","DOI":"10.3201\/eid2607.200841"},{"key":"17892_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.04.004","author":"X Xie","year":"2020","unstructured":"Xie, X. et al. An infectious cDNA clone of SARS-CoV-2. Cell Host Microbe https:\/\/doi.org\/10.1016\/j.chom.2020.04.004 (2020).","journal-title":"Cell Host Microbe"},{"key":"17892_CR11","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.24.006544","author":"S Khan","year":"2020","unstructured":"Khan, S. et al. Analysis of serologic cross-reactivity between common human coronaviruses and SARS-CoV-2 using coronavirus antigen microarray. bioRxiv https:\/\/doi.org\/10.1101\/2020.03.24.006544 (2020).","journal-title":"bioRxiv"},{"key":"17892_CR12","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","volume":"9","author":"J Nie","year":"2020","unstructured":"Nie, J. et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg. Microbes Infect. 9, 680\u2013686 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"17892_CR13","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.22.165712","author":"X Xie","year":"2020","unstructured":"Xie, X. et al. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. bioRxiv https:\/\/doi.org\/10.1101\/2020.06.22.165712 (2020).","journal-title":"bioRxiv"},{"key":"17892_CR14","doi-asserted-by":"crossref","unstructured":"Mulligan, M. J. et al. Phase 1\/2 study of a COVID-19 RNA vaccine candidate (BNT162b1) in adults. Nature (2020). In press.","DOI":"10.1038\/s41586-020-2639-4"},{"key":"17892_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4783","author":"C Shen","year":"2020","unstructured":"Shen, C. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA https:\/\/doi.org\/10.1001\/jama.2020.4783 (2020).","journal-title":"JAMA"},{"key":"17892_CR16","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1128\/JCM.00975-17","volume":"55","author":"C Shan","year":"2017","unstructured":"Shan, C. et al. Evaluation of a novel reporter virus neutralization test for serological diagnosis of Zika and Dengue virus infection. J. Clin. Microbiol. 55, 3028\u20133036 (2017).","journal-title":"J. Clin. Microbiol."},{"key":"17892_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ebiom.2017.03.006","volume":"17","author":"C Shan","year":"2017","unstructured":"Shan, C. et al. A rapid Zika diagnostic assay to measure neutralizing antibodies in patients. EBioMedicine 17, 157\u2013162 (2017).","journal-title":"EBioMedicine"}],"updated-by":[{"DOI":"10.1038\/s41467-021-24287-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17892-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17892-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17892-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T19:23:37Z","timestamp":1670268217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17892-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,13]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["17892"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-17892-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.21.109546","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,13]]},"assertion":[{"value":"20 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-021-24287-2","URL":"https:\/\/doi.org\/10.1038\/s41467-021-24287-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.X., V.D.M., and P.-Y.S. have filed a patent on the reverse genetic system and reporter SARS-CoV-2. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4059"}}